Evidence map›Paper›PMID 40847220›Full record

ArticleBasic research in cardiology2025

Calcific aortic valve disease augments vesicular microRNA-145-5p to regulate the calcification of valvular interstitial cells via cellular crosstalk.

P R Goody, D Christmann, D Goody, S Hildebrand, H Billig, D Nehl, R Chennupati, M Gladka, K Wilhelm-Jüngling, S Uchida and 12 more

Abstract read
In one paragraph

Article in Basic research in cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Pharmaceuticals (Basel, Switzerland) · 2026
    Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

P R GoodyHeart Center Bonn, Molecular Cardiology, Department of Internal Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
D ChristmannHeart Center Bonn, Molecular Cardiology, Department of Internal Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
D GoodyInstitute of Pharmacology and Toxicology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
S HildebrandInstitute of Pharmacology and Toxicology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
H BilligHeart Center Bonn, Molecular Cardiology, Department of Internal Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
D NehlHeart Center Bonn, Molecular Cardiology, Department of Internal Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
R ChennupatiDepartment of Cardiology, Pulmonology and Vascular Medicine, Medical Faculty and University Hospital, Heinrich-Heine University, 40225, Düsseldorf, Germany.
M GladkaDepartment of Medical Biology, Amsterdam University Medical Centers, Amsterdam Cardiovascular Sciences, Meibergdreef 15, 1105 AZ, Amsterdam, The Netherlands.
K Wilhelm-JünglingEndothelial Signaling and Metabolism, Institute for Cardiovascular Sciences, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
S UchidaCenter For RNA Medicine, Department of Clinical Medicine, Aalborg University, Frederikskaj 10B, 2, 2450, Copenhagen SV, Denmark.
S Iris-BibliDepartment of Vascular Dysfunction, European Center for Angioscinece (ECAS), Medical Faculty Mannheim, Heidelberg University, Ludolf-Krehl-Straße 13-17, 68167, Mannheim, Germany.
J B MooreCenter for Cardiometabolic Science, Department of Medicine, University of Louisville, 580 S. Preston Street, Louisville, KY, 40202, USA.
N HamdaniDepartment of Cellular and Translational Physiology, Faculty of Medicine, Institute of Physiology, Universitätsstr. 150, 44801, Bochum, Germany.
F PaneniCenter for Translational and Experimental Cardiology (CTEC), Department of Cardiology, University Hospital Zurich and University of Zürich, Wagistrasse 12, 8952, Schlieren, Switzerland.
S S PullamsettiLung Vascular Epigenetics, Max-Planck-Institute for Heart and Lung Research, Parkstr. 1, 61231, Bad Nauheim, Germany.
S ZimmerHeart Center Bonn, Molecular Cardiology, Department of Internal Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
F JansenHeart Center Bonn, Molecular Cardiology, Department of Internal Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
F BakhtiaryDepartment of Cardiac Surgery, Heart Center Bonn, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
E AikawaDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, 77 Ave Louis Pasteur, NRB 741, Boston, MA, 02115, USA.
A PfeiferInstitute of Pharmacology and Toxicology, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
G NickenigHeart Center Bonn, Molecular Cardiology, Department of Internal Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
M R HosenHeart Center Bonn, Molecular Cardiology, Department of Internal Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. hosenmr@uni-bonn.de.ORCID 0000-0003-2823-0628

Funding

Improving Mitral Compensation In Ischemic RegurgitationR01HL141917 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI AIKAWA, ELENA, BISCHOFF, JOYCE E. · 2018 to 2021
$5.6M
Macrophage-derived microcalcificaitonsR01HL136431 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI AIKAWA, ELENA · 2017 to 2020
$2.7M
New driver of fibrosis and calcification in CAVDR01HL147095 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI AIKAWA, ELENA · 2019 to 2022
$2.4M
Deutsche Forschungsgemeinschaft 397484323 - TRR259 - Project B04NHLBI NIH HHS R01 HL136431NHLBI NIH HHS R01 HL141917NHLBI NIH HHS R01 HL147095
6 · The paper itself

Abstract

Calcific aortic valve disease (CAVD) is one of the leading causes of cardiovascular death in the elderly population worldwide. MicroRNAs (miRNAs) are highly dysregulated in patients with CAVD undergoing surgical aortic valve replacement (SAVR). However, the miRNA-dependent mechanisms regulating inflammation and calcification or miRNA-mediated cell-cell crosstalk during the pathogenesis of CAVD remain poorly understood. Here, we investigated the role of extracellular vesicle (EV)-associated miR-145-5p, which we showed to be strongly upregulated in CAVD in mice and humans during valve calcification. Human TaqMan miRNA arrays identified dysregulated miRNAs in CAVD tissue explants from patients compared to non-calcified (patients with aortic insufficiency) heart valve tissue explants from patients undergoing SAVR. Echocardiographic parameters were measured in conjunction with the quantification of dysregulated miRNAs in a murine CAVD model. In vitro calcification experiments were performed to investigate the effects of EV-miR-145-5p on calcification and crosstalk in heart valve cells. Integrated OMICS analyses were performed to analyze molecular miRNA signatures and their effects on signaling pathways-associated with CAVD. RNA sequencing, high-throughput transcription factor (TF) activity assays, and osteogenesis arrays revealed that a number of genes, miRNAs, TFs are critical for calcification and apoptosis involved in the pathogenesis of CAVD. Among several miRNAs dysregulated in valve explants from CAVD patients, miR-145-5p was the most highly sex-independently upregulated miRNA (AUC, 0.780, p value, 0.01) in patient plasma. Large EV population (170-800 nm) isolated from aortic valve tissues explanted from patients with CAVS (calcific aortic valve stenosis) after SAVR demonstrated a significantly higher level of miR-145-5p expression in comparison to control (vesicle-free plasma). MiRNA arrays utilizing with aortic stenosis samples from patients and mice showed that the expression of miR-145-5p is significantly upregulated and positively correlated with cardiac function based on echocardiography. In vitro experiments confirmed that miR-145-5p is encapsulated in EVs and transported into interstitial cells of the aortic valve. The results of integrated OMICs show that miR-145-5p is related to markers of inflammation, calcification, and apoptosis. In vitro calcification experiments demonstrated that miR-145-5p regulates the ALPL gene, a hallmark of calcification in vascular and heart valve cells. Mechanistically, EV-mediated shuttling of miR-145-5p suppressed the expression of ZEB2, a negative regulator of the ALPL gene, by binding to its 3' untranslated region to inhibit its translation, thereby diminishing the calcification of valvular interstitial cells. Elevated levels of pro-calcific and pro-apoptotic EV-associated miR-145-5p contribute to the progression of CAVD via the ZEB2-ALPL axis, which could potentially be therapeutically targeted to minimize the burden of CAVD.

Indexed as

Aortic ValveAortic Valve DiseaseAortic Valve StenosisCalcinosisCell CommunicationExtracellular VesiclesMicroRNAsAgedAnimalsCells, CulturedDisease Models, AnimalFemaleHumansMaleMiceMice, Inbred C57BLMicroRNAsMIRN145a microRNA, mouseMIRN145 microRNA, humanAortic valve stenosisCellular crosstalkExtracellular vesiclesMicroRNAValvular calcification

Identifiers

PMID40847220
PMCPMC12518376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.